IGC
Innovative Growth Capital
The First Reverse VC Fund
IGC transforms venture into a science - engineered for predictable, accelerated outcomes.
Innovative Growth Capital (IGC) is the first Reverse VC™ fund: purpose-built to align corporate demand with startup capability, accelerate commercialization, and engineer exits earlier by design.
Venture capital was built for a different era.
It assumed long timelines, probabilistic outcomes, and eventual alignment between innovation and buyers.
The market no longer works this way.
Corporates want strategic alignment, technology optionality, and credible acquisition vectors. Corporates Do Not Want Startups - They Want Outcomes.
Founders need faster paths to revenue, relevance, and meaningful exits.
LPs need shorter timelines, faster DPI, predictability, and efficiency.
Reverse VC aligns all three.
Traditional venture relies on pattern matching and hope.
The market now demands precision, speed, and proof.
The Market Moved. The Venture Model Did Not.
Why IGC Created Reverse VC as a New Category
IGC transforms venture into a science — and science accelerates outcomes.
Venture relied on intuition and pattern matching
The market now demands precision, speed, and proof
Reverse VC replaces guesswork with architecture and execution discipline
Demand → commercialization → exit, designed from day one
Outcomes become engineered, not hoped for.
We begin with the exit context — corporate demand, growth objectives, and technology roadmaps — not with capital deployment.
From day one, we engineer commercialization, activate strategic buyers, and shape acquisition pathways — informed by real buyer logic and timing.
This architecture has delivered outcomes across multiple market and technology cycles.
IGC engineers outcomes by design.
What Makes IGC Different
Reverse VC is a Closed Loop System Designed for Outcomes
Science identifies future value.
Commercialization turns insight into relevance.
Exit architecture converts relevance into liquidity.
Catalysts make it all happen.
IGC institutionalizes this closed loop system to produce repeatable outcomes.
How Reverse VC Works
Reverse VC replaces guesswork with execution architecture.
IGC begins where venture typically ends: the exit
By aligning corporate demand, startup capability, commercialization engineering, and exit logic from day one, outcomes become intentional rather than accidental.
Thus the causal chain is explicit and enforced:
Demand → Commercialization → Valuation → Capital → Exit
Demand-Aligned Growth Focus
IGC invests where corporate demand concentrates repeatedly and with conviction — because that demand converts directly into top line revenue and strategic outcomes.
Across cycles, industries, and buyers, demand consistently clusters in three areas:
Health of the Human — neuroscience and neurotechnology; cognitive, mental, and human performance; women’s health; AI-driven health and performance optimization
Health of the Planet — energy transition, new energy sources, and next-generation energy systems; advanced materials; food, agriculture, and supply chain innovation; climate and infrastructure resilience
Transformative Technologies — AI, data science, and advanced compute; next-generation computing and security; autonomy and sensing; and dual-use commercial and defense technologies
These are not themes.
They are areas where corporate demand has already signaled durable, repeatable conviction.
Why It Works
Corporate demand is the strongest leading indicator of future enterprise value
When demand precedes investment:
• Capital efficiency improves
• Time to relevance, exit, and returns compresses
• Strategic alignment increases
• Commercialization and exit pathways are activated earlier by design
Reverse VC aligns incentives across founders, corporates, and investors — structurally.
This structure has delivered outcomes across multiple market and technology cycles.
IGC For Founders
Founders do not need more capital.
They need relevance, traction, and a clear path to outcomes.
IGC works with founders to:
• Align products to real corporate demand
• Accelerate early revenue and strategic validation
• Reduce wasted cycles and unfocused iteration
• Design commercialization and exit pathways early
IGC is built for founders who want to build with intent.
IGC For Corporates
Corporates do not want startups.
They want outcomes.
IGC helps corporates:
• Grow top line revenue
• Identify emerging capabilities aligned to real needs
• Reduce innovation and acquisition risk
• Engage with companies architected for integration
• Create optionality across partnership, investment, and acquisition
IGC transforms innovation into strategic outcomes by design.
IGC For Dual-Use Innovation
Dual-use technologies require precision, trust, and responsible pathways.
IGC supports dual-use innovation by aligning commercial and strategic demand early, designing adoption pathways that respect regulatory realities, and accelerating deployment without compromising integrity.
The IGC Team
Outcome Engineers
With years of proven collaboration and billions in market value created across dozens of companies, the IGC team is a global collective of industry and category experts solving complex challenges and accelerating engineered outcomes.
We do not just invest.
We catalyze alignment, accelerate revenue, and deliver high-impact exits.
Stephen Meyer
Wesley King
Dr. Andy Walshe
Dr. Sue Robson
Lee Esmond
Brad Chedister
Jason Monberg
Liz Dalton
Josh Wachtel
Lionel Conacher
Dr. Galen Buckwalter
Vera Futorjanski
Wayne Pfeffer
Tracy Thie
Taylor Johnson
Peter Goldie
Melissa Barall
Sean Voigt
George B. Reed III
Jose Alvarez
Jeff Sturgeon
Rikin Patel
Ryan McKim
What Comes Next
How corporate demand, technology, and execution are converging.
The market has changed.
Corporates are replacing internal R&D with external capability to drive top line revenue.
Founders need faster paths to relevance and exits.
Investors demand faster returns and better alignment between risk, time, and outcome.
IGC was built for this moment.
We are proactively scaling capabilities — we are not a traditional VC or PE firm.